A phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan.

CONCLUSIONS: We report the first study of chemo-priming with epigenetic therapy in GI cancers. Guadecitabine 45 mg/m2 and irinotecan 125mg/m2 with GFS was safe and tolerable in mCRC patients, with early indication of benefit. These data have provided the basis for an ongoing phase II randomized, multicenter trial. PMID: 30097434 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research